Published in ACS Chem Biol on January 17, 2014
Prospective virtual screening for novel p53-MDM2 inhibitors using ultrafast shape recognition. J Comput Aided Mol Des (2014) 0.85
Fragment-based library generation for the discovery of a peptidomimetic p53-Mdm4 inhibitor. ACS Comb Sci (2014) 0.78
Efficient isocyanide-less isocyanide-based multicomponent reactions. Org Lett (2015) 0.77
Molecular Probing of the HPV-16 E6 Protein Alpha Helix Binding Groove with Small Molecule Inhibitors. PLoS One (2016) 0.75
Focusing on shared subpockets - new developments in fragment-based drug discovery. Expert Opin Drug Discov (2015) 0.75
Discovery of a Potent Allosteric Kinase Modulator by Combining Computational and Synthetic Methods. Angew Chem Int Ed Engl (2015) 0.75
Scaffold hopping via ANCHOR.QUERY: β-lactams as potent p53-MDM2 antagonists(†). Medchemcomm (2017) 0.75
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science (2004) 24.42
Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science (1996) 9.48
Discovering high-affinity ligands for proteins: SAR by NMR. Science (1996) 7.10
Multicomponent Reactions with Isocyanides. Angew Chem Int Ed Engl (2000) 6.15
Structural biology of the tumor suppressor p53. Annu Rev Biochem (2008) 3.36
Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells. Proc Natl Acad Sci U S A (1985) 3.15
The human MDM-2 oncogene is overexpressed in leukemias. Blood (1993) 2.24
Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. J Med Chem (2005) 2.23
High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx. Cell Cycle (2009) 2.11
Immunochemical analysis of the interaction of p53 with MDM2;--fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene (1994) 1.94
The tumor suppressor p53: from structures to drug discovery. Cold Spring Harb Perspect Biol (2010) 1.64
Enabling large-scale design, synthesis and validation of small molecule protein-protein antagonists. PLoS One (2012) 1.60
Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery. Cell Cycle (2010) 1.52
Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. Biochemistry (2001) 1.30
The structure-based design of Mdm2/Mdmx-p53 inhibitors gets serious. Angew Chem Int Ed Engl (2011) 1.30
Robust generation of lead compounds for protein-protein interactions by computational and MCR chemistry: p53/Hdm2 antagonists. Angew Chem Int Ed Engl (2010) 1.29
Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia. Blood (2010) 1.27
Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein interaction. J Med Chem (2009) 1.19
Establishing long-term cultures with self-renewing acute myeloid leukemia stem/progenitor cells. Exp Hematol (2007) 1.16
Application of NMR in structural proteomics: screening for proteins amenable to structural analysis. Structure (2002) 1.15
Concise construction of novel bridged bicyclic lactams by sequenced Ugi/RCM/Heck reactions. Org Lett (2007) 1.10
1,4-Thienodiazepine-2,5-diones via MCR (I): synthesis, virtual space and p53-Mdm2 activity. Chem Biol Drug Des (2010) 1.07
Rapid and efficient hydrophilicity tuning of p53/mdm2 antagonists. J Comb Chem (2010) 1.03
Exhaustive fluorine scanning toward potent p53-Mdm2 antagonists. ChemMedChem (2011) 1.01
Polycyclic indole alkaloid-type compounds by MCR. Chem Commun (Camb) (2009) 1.01
Robust NMR screening for lead compounds using tryptophan-containing proteins. J Am Chem Soc (2009) 0.95
An NMR-based antagonist induced dissociation assay for targeting the ligand-protein and protein-protein interactions in competition binding experiments. J Med Chem (2007) 0.94
Detection of p53 gene mutations by single strand conformational polymorphism (SSCP) in human acute myeloid leukemia-derived cell lines. Leuk Res (2002) 0.93
The MDM-2 antagonist nutlin-3 promotes the maturation of acute myeloid leukemic blasts. Neoplasia (2007) 0.88
Lifeact: a versatile marker to visualize F-actin. Nat Methods (2008) 12.23
Filamins: promiscuous organizers of the cytoskeleton. Trends Biochem Sci (2006) 2.79
Structures of the human and Drosophila 80S ribosome. Nature (2013) 2.36
High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx. Cell Cycle (2009) 2.11
Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain. Cell Cycle (2008) 1.71
Transient protein states in designing inhibitors of the MDM2-p53 interaction. Structure (2013) 1.63
Survivin is a therapeutic target in Merkel cell carcinoma. Sci Transl Med (2012) 1.61
Enabling large-scale design, synthesis and validation of small molecule protein-protein antagonists. PLoS One (2012) 1.60
Molecular basis for the inhibition of p53 by Mdmx. Cell Cycle (2007) 1.55
Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery. Cell Cycle (2010) 1.52
Expansion of the genetic code enables design of a novel "gold" class of green fluorescent proteins. J Mol Biol (2003) 1.34
Structure of the stapled p53 peptide bound to Mdm2. J Am Chem Soc (2011) 1.30
The structure-based design of Mdm2/Mdmx-p53 inhibitors gets serious. Angew Chem Int Ed Engl (2011) 1.30
Practical aspects of the 2D 15N-[1h]-NOE experiment. J Biomol NMR (2002) 1.29
Robust generation of lead compounds for protein-protein interactions by computational and MCR chemistry: p53/Hdm2 antagonists. Angew Chem Int Ed Engl (2010) 1.29
Two strategies for the development of mitochondrion-targeted small molecule radiation damage mitigators. Int J Radiat Oncol Biol Phys (2011) 1.29
Arsenic toxicity at low doses: epidemiological and mode of action considerations. Toxicol Appl Pharmacol (2004) 1.28
Isoquinolin-1-one inhibitors of the MDM2-p53 interaction. ChemMedChem (2008) 1.27
Protein folding and stability of human CDK inhibitor p19(INK4d). J Mol Biol (2002) 1.25
Protein solubility: sequence based prediction and experimental verification. Bioinformatics (2006) 1.23
CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. Blood (2013) 1.16
Hepatosplenic T-cell lymphoma in a patient with Crohn's disease. Nat Rev Gastroenterol Hepatol (2009) 1.15
Application of NMR in structural proteomics: screening for proteins amenable to structural analysis. Structure (2002) 1.15
The crystal structure of the non-liganded 14-3-3sigma protein: insights into determinants of isoform specific ligand binding and dimerization. Cell Res (2005) 1.13
Molecular determinants for the complex formation between the retinoblastoma protein and LXCXE sequences. J Biol Chem (2005) 1.12
Molecular structure of the rod domain of dictyostelium filamin. J Mol Biol (2004) 1.12
Structural basis for the inhibition of insulin-like growth factors by insulin-like growth factor-binding proteins. Proc Natl Acad Sci U S A (2006) 1.11
Active detachment involves inhibition of cell-matrix contacts of malignant melanoma cells by secretion of melanoma inhibitory activity. Lab Invest (2003) 1.10
NMR indicates that the small molecule RITA does not block p53-MDM2 binding in vitro. Nat Med (2005) 1.09
Structural ramification for acetyl-lysine recognition by the bromodomain of human BRG1 protein, a central ATPase of the SWI/SNF remodeling complex. Chembiochem (2007) 1.09
c-Abl phosphorylates Hdmx and regulates its interaction with p53. J Biol Chem (2008) 1.09
Backbone dynamics of green fluorescent protein and the effect of histidine 148 substitution. Biochemistry (2003) 1.08
Role of the ubiquitin-like protein Hub1 in splice-site usage and alternative splicing. Nature (2011) 1.07
Characterization of 14-3-3sigma dimerization determinants: requirement of homodimerization for inhibition of cell proliferation. Cell Cycle (2006) 1.07
1,4-Thienodiazepine-2,5-diones via MCR (I): synthesis, virtual space and p53-Mdm2 activity. Chem Biol Drug Des (2010) 1.07
Shugoshin is a Mad1/Cdc20-like interactor of Mad2. EMBO J (2011) 1.06
Efficient multicomponent reaction synthesis of the schistosomiasis drug praziquantel. Chemistry (2010) 1.06
Efficient and diverse synthesis of indole derivatives. J Org Chem (2009) 1.04
Efficient assembly of iminodicarboxamides by a "truly" four-component reaction. Angew Chem Int Ed Engl (2012) 1.03
Rapid and efficient hydrophilicity tuning of p53/mdm2 antagonists. J Comb Chem (2010) 1.03
Slow exchange in the chromophore of a green fluorescent protein variant. J Am Chem Soc (2002) 1.02
Exhaustive fluorine scanning toward potent p53-Mdm2 antagonists. ChemMedChem (2011) 1.01
Polycyclic indole alkaloid-type compounds by MCR. Chem Commun (Camb) (2009) 1.01
Structures of actin-bound Wiskott-Aldrich syndrome protein homology 2 (WH2) domains of Spire and the implication for filament nucleation. Proc Natl Acad Sci U S A (2010) 1.00
DNA-binding properties of the recombinant high-mobility-group-like AT-hook-containing region from human BRG1 protein. Biol Chem (2006) 0.99
Structure of the N-terminal domain of the FOP (FGFR1OP) protein and implications for its dimerization and centrosomal localization. J Mol Biol (2006) 0.99
Effects of six months of daily low-dose perchlorate exposure on thyroid function in healthy volunteers. J Clin Endocrinol Metab (2006) 0.99
The Gewald multicomponent reaction. Mol Divers (2010) 0.97
Monitoring the effects of antagonists on protein-protein interactions with NMR spectroscopy. J Am Chem Soc (2005) 0.96
Biological evaluation of tubulysin A: a potential anticancer and antiangiogenic natural product. Biochem J (2006) 0.96
Praziquantel and schistosomiasis. ChemMedChem (2010) 0.96
Tritylamine as an ammonia surrogate in the Ugi tetrazole synthesis. Org Lett (2013) 0.96
Structural basis for the regulation of insulin-like growth factors by IGF binding proteins. Structure (2005) 0.95
Design and modular parallel synthesis of a MCR derived alpha-helix mimetic protein-protein interaction inhibitor scaffold. Bioorg Med Chem Lett (2006) 0.95
Robust NMR screening for lead compounds using tryptophan-containing proteins. J Am Chem Soc (2009) 0.95
A novel medium for expression of proteins selectively labeled with 15N-amino acids in Spodoptera frugiperda (Sf9) insect cells. J Biomol NMR (2003) 0.95
Functional and structural characterization of Spl proteases from Staphylococcus aureus. J Mol Biol (2006) 0.95
MCR synthesis of praziquantel derivatives. Chem Biol Drug Des (2012) 0.94
An NMR-based antagonist induced dissociation assay for targeting the ligand-protein and protein-protein interactions in competition binding experiments. J Med Chem (2007) 0.94
Efficient C2 functionalisation of 2H-2-imidazolines. Org Biomol Chem (2007) 0.93
Cyanoacetamide multicomponent reaction (I): Parallel synthesis of cyanoacetamides. J Comb Chem (2009) 0.93
Quantitative analysis of EBV-specific CD4/CD8 T cell numbers, absolute CD4/CD8 T cell numbers and EBV load in solid organ transplant recipients with PLTD. Transpl Immunol (2006) 0.92
Programmed death-1: therapeutic success after more than 100 years of cancer immunotherapy. Angew Chem Int Ed Engl (2014) 0.91